CAJ | 학술논문

随着分子生物学技术的发展,有关再生障碍性贫血(再障)的研究热点转向细胞遗传学,着力于探讨染色体及基因异常对再障的疗效影响.研究发现特定染色体及基因异常会对再障预后的诊断产生影响.另一方面,再障的首选治疗仍是根据不同情况选择免疫抑制治疗或骨髓移植,针对T细胞的特异性抗体正在研究中且疗效肯定.通过完善诊断分型和发展治疗手段,再障患者的生存率将继续提高.
수착분자생물학기술적발전,유관재생장애성빈혈(재장)적연구열점전향세포유전학,착력우탐토염색체급기인이상대재장적료효영향.연구발현특정염색체급기인이상회대재장예후적진단산생영향.령일방면,재장적수선치료잉시근거불동정황선택면역억제치료혹골수이식,침대T세포적특이성항체정재연구중차료효긍정.통과완선진단분형화발전치료수단,재장환자적생존솔장계속제고.
As the techruque of molecular biology developed, the research of aplastic anemia turns to the cytogenetical level. Scientists focused on irwestigating the relationship between the mutation of gene or chromosome and the curative effect of aplastic anemia.The results show that abnormality of particular chrromosome or gene will cause different outcome . On the other hand, the first line therapy of aplastic anemia is still IST or HSCT according to the different situation.The antibody special for T cell is still in studying, and the effect shows well .Through the typing diagnosis consummated, the treating method developed, the survival rate of the patient with apLastic anemia will be advanced.